Works & Process at the Guggenheim, alongside a list of renowned artists, is developing new works on Vermont's Potash Hill.

Guggenheim lowered the firm’s price target on New York Times (NYT) to $52 from $55 and keeps a Neutral rating on the shares. Core news softness ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule ...

The inclusion of the Metropolitan Museum of Art and the Cloisters complements the existing museum options available to Scotch ...

Guggenheim adjusted its outlook for New York Times Company (NYSE:NYT), reducing the price target from $55.00 to $52.00 while maintaining a Neutral rating on the stock. According to InvestingPro data, ...

In an excerpt from this volume of essays, Guy Nordenson explores the traces of history left behind by different construction ...

German Expressionist artist Gabriele Münter was long-overshadowed by her 12-year romance with Wassily Kandinsky. Now she ...

Philanthropists Alfred and Gail Engelberg sold their lakefront Palm Beach home for $23.8 million, a steep discount from its ...

From snubbed Oscar-nominated films to two centuries' worth of women's clothing and lots of photography, there's plenty to ...

Lendlease completed the $320M sale of its U.S. military housing portfolio to Centinel Public Partnerships, an affiliate of ...

The visually striking Fifth Street Pedestrian Bridge will be completed by the summer of 2026. Getting into South Beach is ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.